It’s on the cover of every magazine, on the headline of every newspaper. People can’t stop talking about it, and frankly, we’re getting sick and tired of hearing about it. That’s right, we’re talking, of course, about The Bachelor’s wild finale yesterday, where Peter’s love triangle turned into a messy happily ever after. Absolutely riveting stuff, but enough about Pete being hopelessly in love with two different women. Today, we want to talk about something more relevant to mankind – the “C-word.” Could this possibly explain why Moderna (MRNA) is charging forward in the face of a market that’s presently getting decimated?
Back in 2018, we suggested dollar-cost-averaging into some Moderna stock following their IPO. (As every MBA knows, always remind people about your good calls, and conveniently forget every bad call you’ve ever made.) If you happened to pick up some shares of Moderna back then, you might be wondering what all the hype is about. For example, the Motley Fool published a piece yesterday titled Will Moderna Make a Fortune Off Its Coronavirus Vaccine? which finishes with some hard-hitting advice f
Sign up to our newsletter to get more of our great research delivered straight to your inbox!
Nanalyze Weekly includes useful insights written by our team of underpaid MBAs, research on new disruptive technology stocks flying under the radar, and summaries of our recent research. Always 100% free.
Become a premium member and get access to hundreds of premium articles, reports and additional content.
Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.